DDrare: Database of Drug Development for Rare Diseases

40. 高安動脈炎
［臨床試験数：22，薬物数：46（DrugBank：20），標的遺伝子数：22，標的パスウェイ数：111］

Searched query = "Takayasu arteritis", "Aortitis syndrome", "Pulseless disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZA; Acetate; Adalimumab; Anti-thymocyte globulin; CYC; Clofarabine; Cyclophosphamide; Cyclosporine; DCB; Filgrastim; Glucocorticoids; INFLIXIMAB; Infliximab; Leflunomide; Leflunomide 10mg Tab; MMF; MTX; Methotrexate; Methotrexate Tablets; Methylprednisolone; Naltrexone; Naltrexone Hydrochloride; Placebo; Prednisolone; Prednisone; Prednisone Acetate; Prednisone acetate; Prednisone, cyclophosphamide; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Computed Tomography; Procedure: Digital substraction angiography (DSA); Procedure: Drug coated balloon (DCB); Procedure: Positron Emission Tomography; Radiation: Fluorine F 18 Clofarabine; Remicade; Remicade (anti tumor necrosis factor inhibitor); RoActemra; RoActemra 20mg/ml; TOCILIZUMAB; Tocilizumab; Tocilizumab (MRA-SC); Tofacitinib; Tofacitinib tablet; Upadacitinib; Yellow Fever Vaccine; Yellow Fever vaccine (17D)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04161898 (ClinicalTrials.gov)	February 4, 2020	12/11/2019	A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK)	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu)	Takayasu Arteritis (TAK)	Drug: Upadacitinib;Drug: Placebo for Upadacitinib;Drug: Prednisolone	AbbVie	NULL	Recruiting	18 Years	N/A	All	56	Phase 3	Japan;Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04161898
(ClinicalTrials.gov)

February 4, 2020

12/11/2019

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu)

Takayasu Arteritis (TAK)

Drug: Upadacitinib;Drug: Placebo for Upadacitinib;Drug: Prednisolone

AbbVie

NULL

Recruiting

18 Years

N/A

All

Phase 3

Japan;Korea, Republic of